The historical rank and industry rank for Burning Rock Biotech's FCF Margin % or its related term are showing as below:
FRA:6BU0'
s FCF Margin % Range Over the Past 10 Years
Min: -140.98 Med: -71.73 Max: -6.24
Current: -6.84
During the past 9 years, the highest FCF Margin % of Burning Rock Biotech was -6.24%. The lowest was -140.98%. And the median was -71.73%.
FRA:6BU0's FCF Margin % is ranked worse than 57.14% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.89
vs FRA:6BU0: -6.84
Burning Rock Biotech FCF Margin % Related Terms
Burning Rock Biotech FCF Margin % Historical Data
* Premium members only.
The historical data trend for Burning Rock Biotech's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6BU0 vs FONR, XGN, QUCY: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Burning Rock Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Burning Rock Biotech FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Burning Rock Biotech's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Burning Rock Biotech (FRA:6BU0) has a FCF Margin % of -27.15% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Burning Rock Biotech and its competitors. According to the industry distribution chart, Burning Rock Biotech ranks #116 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 57.1%.
Is Burning Rock Biotech's FCF Margin % too high?
Burning Rock Biotech's current FCF Margin % is -27.15%. Based on the distribution chart, Burning Rock Biotech ranks #116 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Burning Rock Biotech has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's FCF Margin % compare to FONR and XGN?
According to the Medical Diagnostics & Research industry distribution chart, Burning Rock Biotech ranks #116 out of 203 companies for FCF Margin %. This places Burning Rock Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Burning Rock Biotech and its competitors. Burning Rock Biotech's current FCF Margin % is -27.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (FRA:6BU0) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.43, compared to a current price of €6.00 — trading 10.5% above its estimated fair value. The current FCF Margin % is -27.15%. Burning Rock Biotech's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Burning Rock Biotech (FRA:6BU0), the current FCF Margin % is -27.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Burning Rock Biotech (FRA:6BU0) Overvalued in 2026?
Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued.
The current stock price of €6.00 is trading 10.5% above its estimated GF Value™ of €5.43.
GuruFocus considers Burning Rock Biotech to be Modestly Undervalued.
Key valuation signals for FRA:6BU0:
FCF Margin %: -27.15%
GF Value™: €5.43 vs. price of €6.00 (10.5% above fair value)
No single metric tells the full story. See the FRA:6BU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
59GF Score
Get the complete analysis for FRA:6BU0
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6BU0 has been successfully added to your 
